Kyverna Therapeutics licensed a next-generation CD19 CAR T construct from the NIH in January 2022, betting on autoimmune disease before there was much data to back it. That exclusive worldwide license covered autologous and allogeneic rights to a construct the NIH had already shown improved tolerability over its earlier, murine-based construct.
The asset, now called miv-cel, could become the first CAR T therapy approved for an autoimmune indication. Kyverna initiated a rolling BLA submission in May 2026 for stiff person syndrome, a rare disorder affecting roughly 6,000 U.S. patients with no approved treatment and no fallback but a walker or wheelchair for 80% of them. The FDA agreed the single-arm KYSA-8 trial can support approval on its own, with completion targeted for Q4 2026 under RMAT-track priority review.
I’ve watched enough cell therapy programs stall on manufacturing and commercialization to notice the pattern here: Gilead and Bristol Myers Squibb dominate oncology CAR T because scale wins there. Kyverna is starting with a 6,000-patient orphan indication precisely because scale isn’t required yet, it’s a foothold before the company goes after myasthenia gravis, a market already crowded with Amgen, J&J, AstraZeneca and argenx.
Two-thirds of trial patients who needed a mobility aid at baseline walked without one after a single miv-cel infusion, off background immunosuppressants too. If the FDA holds the KYSA-8 data as sufficient, every other autoimmune cell therapy sponsor building a registrational package on a single-arm trial just got a template.
Rebecca Lauren